Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis
- PMID: 26434843
- DOI: 10.7314/apjcp.2015.16.15.6359
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis
Abstract
Background: Preclinical studies have shown that the combination of an aromatase inhibitor (AI) and capecitabine in estrogen receptor (ER)-positive cell lines enhance antitumor efficacy. This retrospective analysis of a group of patients with metastatic breast cancer (MBC) evaluated the efficacy and safety of combined AI with capecitabine.
Materials and methods: Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy.
Results: Of 72 patients evaluated, 31 received the combination treatment, 22 AI and 19 capecitabine. The combination was used in 20 patients as first-line and 11 as second-line treatment. Mean age was 46.2 years with a range of 28-72 years. At the time of progression, 97% had a performance status of <2 and 55% had visceral disease. No significant difference was observed between the three groups according to clinical and pathological features. Mean follow up was 38 months with a range of 16-66 months. The median PFS of first-line treatment was significantly better for the combination (PFS 21 months vs 8.0 months for capecitabine and 15.0 months for AI). For second-line treatment, the PFS was longer in the combination compared with capecitabine and Al groups (18 months vs. 5.0 months vs. 11.0 months, respectively). Median 2 year and 5 year survival did not show any significant differences among combination and monotherapy groups. The most common adverse events for the combination group were grade 1 and 2 hand-for syndrome (69%), grade 1 fatigue (64%) and grade 1 diarrhoea (29%). Three grade 3 hand-foot syndrome events were reported.
Conclusions: Combination treatment with capecitabine and AI used as a first line or second line treatment was safe with much lowered toxicity. Prospective randomized clinical trials should evaluate the use of combination therapy in advanced breast cancer to confirm these findings.
Similar articles
-
Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study.Clin Breast Cancer. 2020 Jun;20(3):228-237. doi: 10.1016/j.clbc.2019.12.012. Epub 2020 Jan 7. Clin Breast Cancer. 2020. PMID: 32005499 Clinical Trial.
-
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.Lancet Oncol. 2017 Jun;18(6):732-742. doi: 10.1016/S1470-2045(17)30312-1. Epub 2017 May 16. Lancet Oncol. 2017. PMID: 28526536 Free PMC article. Clinical Trial.
-
Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.Chin J Cancer. 2016 Apr 25;35:39. doi: 10.1186/s40880-016-0101-7. Chin J Cancer. 2016. PMID: 27112139 Free PMC article.
-
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).Curr Med Res Opin. 2012 Aug;28(8):1263-79. doi: 10.1185/03007995.2012.707643. Epub 2012 Jul 16. Curr Med Res Opin. 2012. PMID: 22738819 Review.
-
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.Health Technol Assess. 2011;15(42):1-93, iii-iv. doi: 10.3310/hta15420. Health Technol Assess. 2011. PMID: 22152751 Free PMC article. Review.
Cited by
-
Association of Cytidine Deaminase Polymorphism with Capecitabine Effectiveness in Breast Cancer Patients.Asian Pac J Cancer Prev. 2023 Dec 1;24(12):4219-4225. doi: 10.31557/APJCP.2023.24.12.4219. Asian Pac J Cancer Prev. 2023. PMID: 38156857 Free PMC article.
-
Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer.Curr Oncol. 2023 Jun 24;30(7):6097-6110. doi: 10.3390/curroncol30070454. Curr Oncol. 2023. PMID: 37504314 Free PMC article.
-
Operations Management Interventions in Cancer Care Delivery in LMICs: The Way Forward.Asian Pac J Cancer Prev. 2023 Jan 1;24(1):1-7. doi: 10.31557/APJCP.2023.24.1.1. Asian Pac J Cancer Prev. 2023. PMID: 36708545 Free PMC article.
-
NCI Summer Curriculum in Cancer Control and Prevention – A Practice Changing Course for Oncologists from Limited Resource Country Like India.Asian Pac J Cancer Prev. 2018 May 26;19(5):1157-1160. doi: 10.22034/APJCP.2018.19.5.1157. Asian Pac J Cancer Prev. 2018. PMID: 29801394 Free PMC article.
-
Impact of Cancer Awareness Drive on Generating Understanding and Improving Screening Practices for Breast Cancer: a Study on College Teachers in India.Asian Pac J Cancer Prev. 2017 Jul 27;18(7):1985-1990. doi: 10.22034/APJCP.2017.18.7.1985. Asian Pac J Cancer Prev. 2017. PMID: 28749636 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical